Current and historical daily PE Ratio for Hunan Er-Kang Pharmaceutical Co Ltd (
) from 2011 to May 17 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Hunan Er-Kang Pharmaceutical stock (SZSE:300267) PE ratio as of May 17 2024 is 0.
More Details
Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) PE Ratio (TTM) Chart
Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) PE Ratio (TTM) Historical Data
View and export this data going back to 2011. Start your Free Trial
Total 1185
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Hunan Er-Kang Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-17 | At Loss | 2024-03-08 | At Loss |
| 2024-05-16 | At Loss | 2024-03-07 | At Loss |
| 2024-05-15 | At Loss | 2024-03-06 | At Loss |
| 2024-05-14 | At Loss | 2024-03-05 | At Loss |
| 2024-05-13 | At Loss | 2024-03-04 | At Loss |
| 2024-05-10 | At Loss | 2024-03-01 | At Loss |
| 2024-05-09 | At Loss | 2024-02-29 | At Loss |
| 2024-05-08 | At Loss | 2024-02-28 | At Loss |
| 2024-05-07 | At Loss | 2024-02-27 | At Loss |
| 2024-05-06 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-08 | At Loss |
| 2024-04-22 | At Loss | 2024-02-07 | At Loss |
| 2024-04-19 | At Loss | 2024-02-06 | At Loss |
| 2024-04-18 | At Loss | 2024-02-05 | At Loss |
| 2024-04-17 | At Loss | 2024-02-02 | At Loss |
| 2024-04-16 | At Loss | 2024-02-01 | At Loss |
| 2024-04-15 | At Loss | 2024-01-31 | At Loss |
| 2024-04-12 | At Loss | 2024-01-30 | At Loss |
| 2024-04-11 | At Loss | 2024-01-29 | At Loss |
| 2024-04-10 | At Loss | 2024-01-26 | At Loss |
| 2024-04-09 | At Loss | 2024-01-25 | At Loss |
| 2024-04-08 | At Loss | 2024-01-24 | At Loss |
| 2024-04-03 | At Loss | 2024-01-23 | At Loss |
| 2024-04-02 | At Loss | 2024-01-22 | At Loss |
| 2024-04-01 | At Loss | 2024-01-19 | At Loss |
| 2024-03-29 | At Loss | 2024-01-18 | At Loss |
| 2024-03-28 | At Loss | 2024-01-17 | At Loss |
| 2024-03-27 | At Loss | 2024-01-16 | At Loss |
| 2024-03-26 | At Loss | 2024-01-15 | At Loss |
| 2024-03-25 | At Loss | 2024-01-12 | At Loss |
| 2024-03-22 | At Loss | 2024-01-11 | At Loss |
| 2024-03-21 | At Loss | 2024-01-10 | At Loss |
| 2024-03-20 | At Loss | 2024-01-09 | At Loss |
| 2024-03-19 | At Loss | 2024-01-08 | At Loss |
| 2024-03-18 | At Loss | 2024-01-05 | At Loss |
| 2024-03-15 | At Loss | 2024-01-04 | At Loss |
| 2024-03-14 | At Loss | 2024-01-03 | At Loss |
| 2024-03-13 | At Loss | 2024-01-02 | At Loss |
| 2024-03-12 | At Loss | 2023-12-29 | At Loss |
| 2024-03-11 | At Loss | 2023-12-28 | At Loss |
Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Hunan Er-Kang Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001781
Share Class Description:
SZSE:300267: Class ACompare
Compare
Traded in other countries / regions
300267.China IPO Date
2011-09-27Description
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers